

**Measure #337: Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier – National Quality Strategy Domain: Effective Clinical Care**

**2017 OPTIONS FOR INDIVIDUAL MEASURES:**  
**REGISTRY ONLY**

**MEASURE TYPE:**

Process

**DESCRIPTION:**

Percentage of patients whose providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient's history to determine if they have had appropriate management for a recent or prior positive test

**INSTRUCTIONS:**

This measure is to be reported a minimum of **once per performance period** for patients with psoriasis and/or psoriatic arthritis seen during the **performance period**. This measure may be reported by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**Measure Reporting:**

The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**

All patients with a diagnosis of psoriasis and/or psoriatic arthritis or rheumatoid arthritis who are on a biologic immune response modifier

***DENOMINATOR NOTE:** A patient would be considered denominator eligible for Measure #337 for reporting purposes, if the patient meets the denominator criteria with diagnosis of psoriasis or psoriatic arthritis or rheumatoid arthritis AND is on a biologic immune response modifier PRESCRIBED BY THE PROVIDER BEING EVALUATED FOR THE MEASURE.*

**Definition:**

**Biologic Immune Response Modifier –**

- 1) TNF-alpha inhibitors, to include, but not limited to Infliximab (Remicade), Adalimumab (Humira), Etanercept (Enbrel), or Golimumab (Simponi), Certolizumab (Cimzia).
- 2) Inhibitors of IL-12 and/or IL-23 or their receptors to include but not limited to Ustekinumab (Stelara).
- 3) B7 inhibitors, to include but not limited to Abatacept (Orencia).
- 4) Inhibitors of IL-17 family members or their receptors.

**Denominator Criteria (Eligible Cases):**

All patients, regardless of age

**AND**

**Diagnosis for psoriasis (ICD-10-CM):** L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9

**OR**

**Diagnosis for psoriatic arthritis (ICD-10-CM):** L40.50, L40.51, L40.52, L40.53, L40.54, L40.59

**OR**

**Diagnosis for rheumatoid arthritis (ICD-10-CM):** M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152,

M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.621, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M05.9, M06.00, M06.011, M06.012, M06.019, M06.021, M06.022, M06.029, M06.031, M06.032, M06.039, M06.041, M06.042, M06.049, M06.051, M06.052, M06.059, M06.061, M06.062, M06.069, M06.071, M06.072, M06.079, M06.08, M06.09, M06.1, M06.20, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.271, M06.272, M06.279, M06.28, M06.29, M06.30, M06.311, M06.312, M06.319, M06.321, M06.322, M06.329, M06.331, M06.332, M06.339, M06.341, M06.342, M06.349, M06.351, M06.352, M06.359, M06.361, M06.362, M06.369, M06.371, M06.372, M06.379, M06.38, M06.39, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.9

**AND**

**Patient encounter during performance period (CPT or HCPCS):** 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, G0402

**WITHOUT**

**Telehealth Modifier:** GQ, GT

**AND**

**Biologic immune response modifier prescribed:** G9506

**NUMERATOR:**

Patients who have a documented negative annual TB screening or have documentation of the management of a positive TB screening test with no evidence of active tuberculosis, confirmed through use of radiographic imaging (i.e., chest x-ray, CT)

**Numerator Options:**

***Performance Met:***

Documentation of negative or managed positive TB screen with further evidence that TB is not active within one year of patient visit (**G9359**)

**OR**

***Performance Not Met:***

No documentation of negative or managed positive TB screen (**G9360**)

**RATIONALE:**

The safety of biologics in terms of their long-term adverse events and their use in different types of psoriasis and in different patient populations is important for clinicians to understand and monitor. Biologics have been associated with a variety of serious and "routine" opportunistic infections, particularly tuberculosis. For this reason, anti-tuberculosis testing both prior to the initiation of a biologic therapy and annually during treatment is pertinent.

### **CLINICAL RECOMMENDATION STATEMENTS:**

When planning to initiate treatment of a patient with psoriasis with a biologic it is important to obtain an age appropriate history and physical examination along with an updated medication list. In addition, it is also important to obtain a reliable set of baseline laboratory studies that will allow the clinician to detect and be aware of any underlying conditions or risk factors. This is particularly important because after patients have been initiated on a biologic treatment, they are likely to be treated with other biologics or systemic therapies and it may be useful to have reliable baseline laboratory studies. Tuberculosis testing (PPD) should be performed on all patients who will be treated with TNF inhibitors as there are reports of tuberculosis reactivation in patients treated with this class of drug. (AAD)

### **COPYRIGHT:**

This Measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

This Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.

Commercial use of this measure requires a license agreement between the user and the American Academy of Dermatology (AAD). Neither the AAD nor its members shall be responsible for any use of the Measure.

AAD encourages use of this Measure by other health care professionals, where appropriate.


### **THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.**

© 2014 American Academy of Dermatology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AAD and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2016 American Medical Association. LOINC® copyright 2004-2016 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2016 College of American Pathologists. All Rights Reserved.

**2017 Registry Individual Measure Flow**  
**#337: Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis**  
**Patients on a Biologic Immune Response Modifier**



**SAMPLE CALCULATIONS:**

**Data Completeness=**

Performance Met (a=4 patients) + Performance Not Met (c=3 patients) = 7 patients = **87.50%**  
 Eligible Population / Denominator (d=8 patients) = 8 patients

**Performance Rate=**

Performance Met (a=4 patients) = 4 patients = **57.14%**  
 Data Completeness Numerator (7 patients) = 7 patients

\*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.  
 The measure diagrams were developed by CMS as a supplemental resource to be used  
 in conjunction with the measure specifications. They should not be used alone or as a  
 substitution for the measure specification.

v1

## 2017 Registry Individual Measure Flow

### #337: Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier

Please refer to the specific section of the Measure Specification to identify the Denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator
2. Check Diagnosis:
  - a. If Diagnosis of Psoriasis equals No, proceed to Check Diagnosis.
  - b. If Diagnosis of Psoriasis equals Yes, proceed to check Encounter
3. Check Diagnosis:
  - a. If Diagnosis of Psoriatic Arthritis equals No, proceed to Check Diagnosis.
  - b. If Diagnosis of Psoriatic Arthritis equals Yes, proceed to check Encounter
4. Check Diagnosis:
  - a. . If Diagnosis of Rheumatoid Arthritis equals No, do not include in Eligible Population or Denominator. Stop Processing.
  - b. If Diagnosis of Rheumatoid Arthritis equals Yes, proceed to check Encounter.
5. Check Encounter:
  - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population or Denominator. Stop Processing.
  - b. If Encounter as Listed in the Denominator equals Yes, proceed to Telehealth Modifier.
6. Check Telehealth Modifier:
  - a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing
  - b. If Telehealth Modifier equals No, proceed to check Biologic Immune Response Modifier Prescribed.
7. Check Biologic immune response modifier prescribed:
  - a. If Biologic Immune Response Modifier Prescribed equals No, do not include in Eligible Population or Denominator. Stop Processing.
  - b. If Biologic Immune Response Modifier Prescribed equals Yes, include in the Eligible population or Denominator.
8. Denominator Population:
  - a. Eligible population or Denominator is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.
9. Start Numerator

10. Check Documentation of Negative or Managed Positive TB Screen with Further Evidence that TB is Not Active within One Year of Patient Visit:
  - a. If Check Documentation of Negative or Managed Positive TB Screen with Further Evidence that TB is Not Active within One Year of Patient Visit equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 patients in Sample Calculation.
  - c. If Check Documentation of Negative or Managed Positive TB Screen with Further Evidence that TB is Not Active within One Year of Patient Visit equals No, proceed to Check No Documentation of Negative or Managed Positive TB Screen.
11. Check No Documentation of Negative or Managed Positive TB Screen:
  - a. If No Documentation of Negative or Managed Positive TB Screen equals Yes, include in Data Completeness Met and Performance Not Met.
  - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 3 patients in the Sample Calculation.
  - c. If No Documentation of Negative or Managed Positive TB Screen equals No, proceed to Data Completeness Not Met.
12. Check Data Completeness Not Met:
  - a. If Data Completeness Not Met, the Quality Data Code or equivalent was not reported. 1 patient has been subtracted from the data completeness numerator in sample calculation.

**SAMPLE CALCULATIONS:**

**Data Completeness=**

$$\frac{\text{Performance Met (a=4 patients)} + \text{Performance Not Met (c=3 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{7 \text{ patients}}{8 \text{ patients}} = 87.50\%$$

**Performance Rate=**

$$\frac{\text{Performance Met (a=4 patients)}}{\text{Data Completeness Numerator (7 patients)}} = \frac{4 \text{ patients}}{7 \text{ patients}} = 57.14\%$$